Related Experiment Video
Updated: Apr 11, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Therapeutic targets of triple-negative breast cancer: a review
Vinayak S Jamdade1, Nikunj Sethi2,3, Nitin A Mundhe1
1Laboratory of Molecular Pharmacology and Toxicology, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati Medical College, Guwahati, India.
Abstract:
Breast cancer (BC) is the second most common cause of cancer deaths. Triple-negative breast cancer (TNBC) does not show immunohistochemical expression of oestrogen receptors, progesterone receptors or HER2. At present, no suitable treatment option is available for patients with TNBC. This dearth of effective conventional therapies for the treatment of advanced stage breast cancer has provoked the development of novel strategies for the management of patients with TNBC. This review presents recent information associated with different therapeutic options for the treatment of TNBC focusing on promising targets such as the Notch signalling, Wnt/β-catenin and Hedgehog pathways, in addition to EGFR, PARP1, mTOR, TGF-β and angiogenesis inhibitors.
Insights
Triple-negative breast cancer (TNBC) lacks effective treatments. This review explores novel therapeutic strategies targeting pathways like Notch, Wnt/β-catenin, and Hedgehog, alongside specific inhibitors for advanced breast cancer management.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Breast cancer (BC) is a leading cause of cancer mortality.
- Triple-negative breast cancer (TNBC) lacks targeted therapies due to absent estrogen receptors, progesterone receptors, and HER2.
- Current treatment options for advanced TNBC are limited, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review emerging therapeutic strategies for triple-negative breast cancer.
- To highlight promising molecular targets and drug candidates for TNBC treatment.
- To provide an overview of recent advancements in managing advanced breast cancer.
Main Methods:
- Literature review of recent scientific publications.
- Analysis of therapeutic targets in triple-negative breast cancer.
- Synthesis of information on novel treatment modalities.
Main Results:
- Identified key signaling pathways including Notch, Wnt/β-catenin, and Hedgehog as potential targets.
- Highlighted the role of inhibitors targeting EGFR, PARP1, mTOR, TGF-β, and angiogenesis.
- Summarized promising therapeutic options for TNBC.
Conclusions:
- Novel therapeutic strategies targeting specific molecular pathways show promise for TNBC treatment.
- Targeted therapies offer potential for improved outcomes in advanced breast cancer.
- Further research into these targets is crucial for developing effective TNBC therapies.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
03:08Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025